Literature DB >> 1951334

Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy.

S Oikawa1, N Suzuki, E Sakuma, T Saito, K Namai, H Kotake, Y Fujii, T Toyota.   

Abstract

Recently, two cases of renal disease were observed in which there was an abnormal accumulation of lipids, "lipoprotein thrombi," in the glomerular capillary lumen. This disease has been designated as lipoprotein glomerulopathy. Four other cases have been diagnosed independently by renal histology in other clinical laboratories. All six patients showed proteinuria (1.6 to 10 g/d), normal lecithin-cholesterol acyltransferase (LCAT) activity, type III hyperlipoproteinemia-like lipoprotein profiles, and significantly (P less than 0.01) higher levels of plasma apolipoprotein (apo) E (greater than 10 mg/dL) compared with the control patients with hyperlipidemic nephrotic syndrome without lipoprotein thrombi and type IIb hyperlipoproteinemia without renal disease. Lipoprotein glomerulopathy is not familial type III hyperlipoproteinemia (dysbetalipoproteinemia), because apolipoprotein E3 is present. Apo E isoforms were all rare: five cases of E2/3 and one case of E4/4. These results suggest that excessive apo E is associated with apo E isoform and lipoprotein metabolic derangement in such a renal disease. Further studies are needed on the relationship between the apo E hyperlipoproteinemia and the formation of lipoprotein thrombi.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951334     DOI: 10.1016/s0272-6386(12)80649-4

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy.

Authors:  Yoshiro Miyahara; Shinsuke Nishimura; Maho Watanabe; Kenji Ito; Hitoshi Nakashima; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2011-11-11       Impact factor: 2.801

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.

Authors:  Atsunori Ishimura; Maho Watanabe; Hitoshi Nakashima; Kenji Ito; Katsuhisa Miyake; Shizue Mochizuki; Yasushi Ishigaki; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2009-05-21       Impact factor: 2.801

4.  A Common APOE Polymorphism Is an Independent Risk Factor for Reduced Glomerular Filtration Rate in the Spanish RENASTUR Cohort.

Authors:  Eliecer Coto; Juan Gómez; Beatriz Tavira; Salvador Tranche; Francisco Ortega; María I Rodríguez; Emilio Sánchez; Rafael Marín; Ana I Corao; Jorge Arenas; Victoria Alvarez
Journal:  Cardiorenal Med       Date:  2013-05-16       Impact factor: 2.041

Review 5.  Topics in lipoprotein glomerulopathy: an overview.

Authors:  Takao Saito; Akira Matsunaga; Kenji Ito; Hitoshi Nakashima
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

6.  In silico analyses of deleterious missense SNPs of human apolipoprotein E3.

Authors:  Allan S Pires; William F Porto; Octavio L Franco; Sérgio A Alencar
Journal:  Sci Rep       Date:  2017-05-30       Impact factor: 4.379

7.  Lipoprotein Glomerulopathy in a Hispanic Female: A Case Report and Literature Review.

Authors:  Nasma K Majeed; Jeanette McLaughlin; Miguel Gonzalez
Journal:  Can J Kidney Health Dis       Date:  2019-06-27

8.  Lipoprotein glomerulopathy resulting from compound heterogeneous mutations of APOE gene: A case report.

Authors:  Yunsi Li; Jin Chen; Yurong Zou; Wei Wang; Guisen Li
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.